RxCelerate’s new company values, co-created by our people
Cambridge, UK, July 2024
We are pleased to share our new company values – to support us as we continue building and developing as a people-first organisation.
These values were shaped through a collaborative, company-wide initiative, where every employee was invited to contribute. We held a ‘World Café’ – a structured forum for encouraging open, group dialogue – where we brought together RxCelerate employees from every department. This allowed our staff to share their ideas, insights, and aspirations, collectively shaping the values that will underpin every aspect of the company’s operations.
“We wanted this to be more than just leadership-driven; we wanted everyone in the company to feel ownership over these values.” said Jill Reckless, CEO of RxCelerate. “I believe that through this collaborative process, we’ve created values that truly reflect our inclusive culture which prioritises collaboration, innovation and scientific excellence.”
The People First team said: “We value being the link between everyone at RxCelerate and the Senior management team to make sure all voices are heard. It has been a great privilege to be involved in the process of shaping and embedding the values within the company. It’s exciting to be part of RxCelerate’s growth into a truly people-first organisation and to see the changes we have put forward being implemented.”
RxCelerate is committed to making these values more than just words by embedding them into every aspect of our business, from supporting our team, working with clients, and our ultimate mission of improving patients’ lives.
Read more about our company values.
Notes for Editors
RxCelerate is an outsourced drug discovery and development company based in Cambridge, UK, founded in 2013. It has rapidly grown to become one of the leading providers of drug discovery and development services in the UK. RxCelerate operates a unique model, offering collaborative strategic thinking to clients to help design and execute every aspect of their research and development plans.
RxCelerate offers a comprehensive suite of services covering the entire discovery and development spectrum, including in silico design and discovery, antibody discovery, synthetic and medicinal chemistry, bioanalysis, in vitro services, preclinical services, and project management. Clients can also access RxCelerate’s proprietary platform technologies, including RxNfinity™ for rapid in silico screening, the Galaxy® platform for generating diverse ‘clinic-ready’ antibodies, and ProQuant® for precise bottom-up proteomics across diverse biological samples. The combination of integrated teams and unique technologies allows RxCelerate to deliver pharma-grade drug candidates quickly and at a fraction of the cost of traditional approaches.
RxCelerate has a team of more than 100 employees based in 25,000 square feet of premium laboratory and office space in the Dorothy Hodgkin Building at the Babraham Research Campus, approximately five miles south of Cambridge, UK, as well as offices in Boston, MA.
For more information, please visit www.rxcelerate.com or contact us at [email protected].